Nayan Lamba1,2,3, Paul J Catalano4, Daniel N Cagney3, Daphne A Haas-Kogan3, Ellen J Bubrick5, Patrick Y Wen6, Ayal A Aizer3. 1. Harvard Radiation Oncology Program, Boston, Massachusetts nlamba@partners.org. 2. Department of Medicine, Cambridge Hospital, Cambridge Health Alliance, Cambridge, Massachusetts. 3. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVE: To test the hypothesis that subets of patients with brain metastases (BrM) without seizures at intracranial presentation are at increased risk for developing seizures, we characterized the incidence and risk factors for seizure development among seizure-naïve patients with brain metastases (BrM). METHODS: We identified 15,863 and 1,453 patients with BrM utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2008-2016) and Brigham and Women's Hospital/Dana Farber Cancer Institute (2000-2015) institutional data, respectively. Cumulative incidence curves and Fine/Gray's competing risks regression were used to characterize seizure incidence and risk factors, respectively. RESULTS: Among SEER-Medicare and institutional patients, 1,588 (10.0%) and 169 (11.6%) developed seizures, respectively. On multivariable regression of the SEER-Medicare cohort, African American vs. White race (hazard ratio [HR]=1.45 [95% CI, 1.22-1.73], p<0.001), urban vs. non-urban residence (HR=1.41 [95% CI, 1.17-1.70], p<0.001), melanoma vs. NSCLC as primary tumor type (HR=1.44 [95% CI, 1.20-1.73], p<0.001), and receipt of brain-directed stereotactic radiation (HR=1.67 [95% CI, 1.44-1.94], p<0.001) were associated with greater seizure risk. On multivariable regression of the institutional cohort, melanoma vs. NSCLC (HR=1.70 [95% CI, 1.09-2.64], p=0.02), >4 BrM at diagnosis (HR=1.60 [95% CI, 1.12-2.29], p=0.01), presence of BrM in a high-risk location (HR=3.62 [95% CI, 1.60-8.18], p=0.002), and lack of local brain-directed therapy (HR=3.08 [95% CI, 1.45-6.52], p=0.003) were associated with greater risk of seizure development. CONCLUSIONS: The role of antiseizure medications among select patients with BrM should be re-explored, particularly for those with melanoma, a greater intracranial disease burden, and/or BrM in high-risk locations.
OBJECTIVE: To test the hypothesis that subets of patients with brain metastases (BrM) without seizures at intracranial presentation are at increased risk for developing seizures, we characterized the incidence and risk factors for seizure development among seizure-naïve patients with brain metastases (BrM). METHODS: We identified 15,863 and 1,453 patients with BrM utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2008-2016) and Brigham and Women's Hospital/Dana Farber Cancer Institute (2000-2015) institutional data, respectively. Cumulative incidence curves and Fine/Gray's competing risks regression were used to characterize seizure incidence and risk factors, respectively. RESULTS: Among SEER-Medicare and institutional patients, 1,588 (10.0%) and 169 (11.6%) developed seizures, respectively. On multivariable regression of the SEER-Medicare cohort, African American vs. White race (hazard ratio [HR]=1.45 [95% CI, 1.22-1.73], p<0.001), urban vs. non-urban residence (HR=1.41 [95% CI, 1.17-1.70], p<0.001), melanoma vs. NSCLC as primary tumor type (HR=1.44 [95% CI, 1.20-1.73], p<0.001), and receipt of brain-directed stereotactic radiation (HR=1.67 [95% CI, 1.44-1.94], p<0.001) were associated with greater seizure risk. On multivariable regression of the institutional cohort, melanoma vs. NSCLC (HR=1.70 [95% CI, 1.09-2.64], p=0.02), >4 BrM at diagnosis (HR=1.60 [95% CI, 1.12-2.29], p=0.01), presence of BrM in a high-risk location (HR=3.62 [95% CI, 1.60-8.18], p=0.002), and lack of local brain-directed therapy (HR=3.08 [95% CI, 1.45-6.52], p=0.003) were associated with greater risk of seizure development. CONCLUSIONS: The role of antiseizure medications among select patients with BrM should be re-explored, particularly for those with melanoma, a greater intracranial disease burden, and/or BrM in high-risk locations.
Authors: M J Glantz; B F Cole; P A Forsyth; L D Recht; P Y Wen; M C Chamberlain; S A Grossman; J G Cairncross Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: Nayan Lamba; Rachel B Kearney; Elie Mehanna; Paul J Catalano; Daphne A Haas-Kogan; Daniel N Cagney; Ayal A Aizer Journal: Neuro Oncol Date: 2020-04-15 Impact factor: 12.300
Authors: Nils D Arvold; Nancy E Pinnell; Anand Mahadevan; Sheila Connelly; Rachel Silverman; Stephanie E Weiss; Paul J Kelly; Brian M Alexander Journal: Pract Radiat Oncol Date: 2015-11-10
Authors: M Maschio; L Dinapoli; S Gomellini; V Ferraresi; F Sperati; A Vidiri; P Muti; B Jandolo Journal: J Neurooncol Date: 2009-11-24 Impact factor: 4.130
Authors: Peter A Forsyth; Susan Weaver; Dorcas Fulton; Penelope M A Brasher; Garnette Sutherland; Doug Stewart; Neil A Hagen; Penny Barnes; J Greg Cairncross; Lisa M DeAngelis Journal: Can J Neurol Sci Date: 2003-05 Impact factor: 2.104
Authors: Jeffrey H Silber; Paul R Rosenbaum; Amy S Clark; Bruce J Giantonio; Richard N Ross; Yun Teng; Min Wang; Bijan A Niknam; Justin M Ludwig; Wei Wang; Orit Even-Shoshan; Kevin R Fox Journal: JAMA Date: 2013-07-24 Impact factor: 56.272
Authors: Brett E Youngerman; Evan F Joiner; Xianling Wang; Jingyan Yang; Mary R Welch; Guy M McKhann; Jason D Wright; Dawn L Hershman; Alfred I Neugut; Jeffrey N Bruce Journal: J Neurooncol Date: 2019-12-13 Impact factor: 4.130
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029